Taken together, given what we know about SGLT2 inhibitors, TGF activation might be a component of the beneficial renal effects of SGLT2 inhibitors in diabetic nephropathy, but other mechanisms are likely and will be discussed. This evidence concerns the gene SLC5A2 and diabetic kidney disease.